Implementing Best Practices for Co-Prescribing Naloxone in Your Agency [For General Providers]

This self-paced learning module will provide a standardized, evidence-based curriculum to train healthcare providers, administrators, and executives across a variety of settings on how to implement and sustain a naloxone co-prescribing program in their agency. This module will include topics such as: an overview and history of naloxone utilization, how naloxone co-prescription can function as a solution to the current opioid crisis, overview and examples of implementation frameworks and their applications to a co-prescribing program,  barriers to program implementation, and the importance of stigma reduction in facilitating these programs. This module is part of a compendium of materials produced by the New Jersey Overdose Treatment Collaborative under the NeuroMusculoskeletal institute (NMI) at Rowan University School of Osteopathic Medicine and the Substance Abuse and Mental Health Services Administration (SAMHSA). These resources are intended to provide guidance on co-prescribing naloxone to patients with substance use disorder and those on opioid therapy.

Target Audience: New Jersey Physicians, Advanced Practice Nurses, Podiatrists, Physician Assistants, Clinical Psychologists, Healthcare Administrators and Executives.

Learning Objectives:

1. Recognize the importance of co-prescribing naloxone for patients with chronic pain and substance use disorder (SUD) in our current healthcare landscape.
2. Outline legal considerations for co-prescribing naloxone in New Jersey along with national, state, and organizational recommendations.
3. Identify and Explore the best practices for co-prescribing naloxone in your agency.
4. Recognize the importance of implementing a naloxone co-prescribing program in your agency.
5. Identify important steps that should be considered when implementing a naloxone co-prescribing program.
6. Understand the process of using implementation science to establish a framework for a successful naloxone co-prescribing program.
7. Understand how to identify strategies and barriers to implementing a successful naloxone co-prescribing program in your agency.

Available credit: 1 AOA Category 1-B credit / 1 AMA PRA Category 1 Credit™

• Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
• Rowan-Virtua SOM designates this activity for a maximum of 1 AOA Category 1-B credit and will report CME and specialty credits commensurate with the extent of the physician’s participation in the activity.
• Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
• Rowan-Virtua SOM designates this internet enduring activity for 1 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants must complete an Attestation Form, an Outcome Survey, and an Evaluation to receive a CME certificate.

Certificate of Completion: Participants will receive their certificate of completion upon the completion of their pre and post assessment in the course.

Hearing Impaired Registrants: This enduring course contains closed captioning.

Enduring Course will open: Thursday, May 23, 2023